Current Gastroenterology Reports

, Volume 4, Issue 5, pp 420–426

Adjuvant chemotherapy for colorectal cancer

  • Anne Demols
  • Jean-Luc Van Laethem
Article

Abstract

Colorectal cancer is the second leading cause of cancer death in Western countries. If surgery remains the only cure, recurrence rates for colon cancer range from 30% to 60% for stage III tumors. Adjuvant chemotherapy is the standard treatment for stage III colon tumors and consists of monthly administration of bolus 5-fluorouracil and leucovorin for 5 consecutive days a month over a 6-month period (Mayo regimen). Adjuvant chemotherapy for stage II colon cancer remains controversial, and its administration is not routinely recommended except in certain high-risk and selected patients. Immunotherapy, new drug-based therapies or combinations, and cyclooxygenase-2 inhibitors are being tested in the adjuvant setting. Total mesorectum excision is now the gold standard surgical technique for rectal cancer resection, and this procedure has dramatically decreased local recurrence. Nevertheless, adjuvant chemoradiotherapy is commonly indicated in the United States. In Europe, neoadjuvant radiotherapy is recommended for stage II and III resectable rectal cancers; the role of chemotherapy remains mostly investigational.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Midgley R, Kerr D: Colorectal cancer. Lancet 1999, 353:391–399.PubMedCrossRefGoogle Scholar
  2. 2.
    Deans GT, Parks TG, Rowlands BJ, Spence RA: Prognostic factors in colorectal cancer. Br J Surg 1992, 79:608–613.PubMedCrossRefGoogle Scholar
  3. 3.
    Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352–358.PubMedCrossRefGoogle Scholar
  4. 4.
    Taal BG, Van Tinteren H, Zoetmulder FA: Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001, 85:1437–1443.PubMedCrossRefGoogle Scholar
  5. 5.
    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Lancet 1995, 345:939–944.Google Scholar
  6. 6.
    Francini G, Petrioli R, Lorenzini L, et al.: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994, 106:899–906.PubMedGoogle Scholar
  7. 7.
    O’Connell MJ, Mailliard JA, Kahn MJ, et al.: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246–250.PubMedGoogle Scholar
  8. 8.
    Wolmark N, Rockette H, Mamounas E, et al.: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553–3559. This NSABP randomized trial including 2151 stage II and III patients demonstrates the efficacy of the regimen and its superiority in comparison with 5-FU/levamisole-based chemotherapy.PubMedGoogle Scholar
  9. 9.
    Haller PJ, Catalano JS, Macdonald RJ, et al.: Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: five-year final report of INT-0089 [abstract]. Proc ASCO 1998, 17:982.Google Scholar
  10. 10.
    QUASAR Collaborative Group: Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000, 355:1588–1596. This randomized trial shows the absence of advantage (on DFS and OS) of adding levamisole to 5-FU/LV-based chemotherapy.CrossRefGoogle Scholar
  11. 11.
    O’Connell MJ, Laurie JA, Kahn M, et al.: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998, 16:295–300.PubMedGoogle Scholar
  12. 12.
    Andre T, Colin P, Louvet C, et al.: Phase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucovorin high dose in patients with Dukes B2 and C colon cancer [abstract]. Proc ASCO 2002, 21:529.Google Scholar
  13. 13.
    Midgley R, Kerr D: Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 2001, 10:1011–1019.PubMedCrossRefGoogle Scholar
  14. 14.
    Moertel CG, Fleming TR, Macdonald JS, et al.: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995, 13:2936–2943.PubMedGoogle Scholar
  15. 15.
    Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999, 17:1356–1363.Google Scholar
  16. 16.
    Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349–1355.PubMedGoogle Scholar
  17. 17.
    Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196–1206. Retention of 18q allele, MSI status, and outcome after adjuvant 5-FUbased chemotherapy in stage III colon cancer are described.PubMedCrossRefGoogle Scholar
  18. 18.
    Hemminki A, Mecklin JP, Jarvinen H, et al.: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000, 119:921–928.PubMedCrossRefGoogle Scholar
  19. 19.
    Lenz HJ, Danenberg KD, Leichman CG, et al.: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998, 4:1227–1234.PubMedGoogle Scholar
  20. 20.
    Salonga D, Danenberg KD, Johnson M, et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6:1322–1327.PubMedGoogle Scholar
  21. 21.
    Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al.: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998, 339:223–228.PubMedCrossRefGoogle Scholar
  22. 22.
    Funaki NO, Tanaka J, Ohshio G, et al.: Cytokeratin 20 mRNA in peripheral venous blood of colorectal carcinoma patients. Br J Cancer 1998, 77:1327–1332.PubMedGoogle Scholar
  23. 23.
    Rosenberg R, Hoos A, Mueller J, et al.: Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 2002, 20:1049–1055.PubMedCrossRefGoogle Scholar
  24. 24.
    Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite instability and the benefit of 5-FU based chemotherapy in stage II and III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials [abstract]. Proc ASCO 2002, 21:509.Google Scholar
  25. 25.
    Wolmark N, Bryant J, Smith R, et al.: Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998, 90:1810–1816.PubMedCrossRefGoogle Scholar
  26. 26.
    Hoover HC Jr, Brandhorst JS, Peters LC, et al.: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993, 11:390–399.PubMedGoogle Scholar
  27. 27.
    Vermorken JB, Claessen AM, Van Tinteren H, et al.: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999, 353:345–350.PubMedCrossRefGoogle Scholar
  28. 28.
    Hanna MG Jr, Hoover HC Jr, Vermorken JB, et al.: Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001, 19:2576–2582.PubMedCrossRefGoogle Scholar
  29. 29.
    Riethmuller G, Schneider-Gadicke E, Schlimok G, et al.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994, 343:1177–1183.PubMedCrossRefGoogle Scholar
  30. 30.
    Riethmuller G, Holz E, Schlimok G, et al.: Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998, 16:1788–1794.PubMedGoogle Scholar
  31. 31.
    Punt CJA, Nagy A, Douillard JY, et al.: Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study [abstract]. Proc ASCO 2001, 19:487.Google Scholar
  32. 32.
    Sargent DJ, Goldberg RM, Jacobson SD, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091–1097. Selected elderly patients have the same benefit of a 5-FU-based chemotherapy as do younger patients, without significant increase in toxic effects.PubMedCrossRefGoogle Scholar
  33. 33.
    Popescu RA, Norman A, Ross PJ, et al.: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999, 17:2412–2418.PubMedGoogle Scholar
  34. 34.
    de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947.PubMedGoogle Scholar
  35. 35.
    Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041–1047.PubMedCrossRefGoogle Scholar
  36. 36.
    Van Cutsem E, Twelves C, Cassidy J, et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097–4106.PubMedGoogle Scholar
  37. 37.
    Kargman SL, O’Neill GP, Vickers PJ, et al.: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995, 55:2556–2559.PubMedGoogle Scholar
  38. 38.
    Reddy BS, Hirose Y, Lubet R, et al.: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000, 60:293–297.PubMedGoogle Scholar
  39. 39.
    Taketo MM: COX-2 and colon cancer. Inflamm Res 1998, 47(suppl 2):S112-S116.PubMedCrossRefGoogle Scholar
  40. 40.
    Giovannucci E, Rimm EB, Stampfer MJ, et al.: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994, 121:241–246.PubMedGoogle Scholar
  41. 41.
    Giardiello FM, Hamilton SR, Krush AJ, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313–1316.PubMedCrossRefGoogle Scholar
  42. 42.
    Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946–1952.PubMedCrossRefGoogle Scholar
  43. 43.
    Sugarbaker PH, Gianola FJ, Speyer JC, et al.: Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985, 98:414–422.PubMedGoogle Scholar
  44. 44.
    Vaillant JC, Nordlinger B, Deuffic S, et al.: Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg 2000, 231:449–456.PubMedCrossRefGoogle Scholar
  45. 45.
    Rougier P, Sahmoud T, Nitti D, et al.: Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Intervention Oncologia, and the Japanese Foundation for Cancer Research. Lancet 1998, 351:1677–1681.PubMedCrossRefGoogle Scholar
  46. 46.
    Metzger U, Mermillod B, Aeberhard P, et al.: Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality. World J Surg 1987, 11:452–458.PubMedCrossRefGoogle Scholar
  47. 47.
    Gerard A, Buyse M, Nordlinger B, et al.: Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988, 208:606–614.PubMedCrossRefGoogle Scholar
  48. 48.
    Heald RJ, Husband EM, Ryall RD: The mesorectum in rectal cancer surgery: the clue to pelvic recurrence? Br J Surg 1982, 69:613–616. Description of the TME surgical resection.PubMedCrossRefGoogle Scholar
  49. 49.
    O’Connell MJ, Martenson JA, Wieand HS, et al.: Improving adjuvant therapy for rectal cancer by combining protractedinfusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331:502–507.PubMedCrossRefGoogle Scholar
  50. 50.
    Douglass HO Jr, Moertel CG, Mayer RJ, et al.: Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986, 315:1294–1295.PubMedCrossRefGoogle Scholar
  51. 51.
    Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997, 336:980–987.Google Scholar
  52. 52.
    Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638–646. Short-term preoperative radiation (five 5-Gy doses) reduces the risk of local recurrence after TME.PubMedCrossRefGoogle Scholar
  53. 53.
    Francois Y, Nemoz CJ, Baulieux J, et al.: Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999, 17:2396.PubMedGoogle Scholar
  54. 54.
    van de Velde CJ: Preoperative radiotherapy and TME-surgery for rectal cancer: detailed analyses in relation to quality control in a randomized trial [abstract]. Proc ASCO 2002, 21:506.Google Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Anne Demols
    • 1
  • Jean-Luc Van Laethem
    • 1
  1. 1.Department of GastroenterologyErasme University HospitalBrusselsBelgium

Personalised recommendations